Αρχική World News Three cancer drugs approved for NHS use in Scotland

Three cancer drugs approved for NHS use in Scotland

Lung cancer cells

Lung cancer cells under a microscope. Credit: LRI EM Unit

3 new cancer drugs have been given the go-ahead by the Scottish Medicines Consortium (SMC) for routine use in Scotland, but a fourth has been rejected.

The approved drugs are:

  • Atezolizumab (Tecentriq) for adults with non small cell lung cancer that has spread to another part of their body;
  • Osimertinib (Tagrisso) for adults whose non small cell lung cancer tests positive for a faulty version of a molecule called EGFR;
  • Pembrolizumab (Keytruda) for patients aged 3 years or older with classical Hodgkin lymphoma, a cancer of the white blood cells, that has come back or doesn’t respond to treatment.

Scott Muir, the vice-chairman of the consortium, said he was pleased to be able to accept their use for the NHS in Scotland.

The rejected drug, selpercatinib (Retevno), was being considered for adults with a type of advanced non small cell lung cancer.

“We were unable to accept selpercatinib as the evidence provided by the company was not strong enough to satisfy the committee of its cost effectiveness,” said Muir.

Personalising lung cancer treatment

David Ferguson, public affairs manager for Cancer Research UK in Scotland, said the acceptance of the 2 lung cancer drugs “will be warmly welcomed by patients and their families”.

Whilst both approved to treat lung cancer, the drugs, atezolizumab and osimertinib, work in different ways and are only to be used in people with particular types of lung cancer.

Atezolizumab is a type of immunotherapy. It works by blocking a molecule that’s often found on cancer cells – called PD-L1 – from interacting with immune cells and stopping them from working properly, boosting the immune system’s ability to attack cancer cells.

It has been approved for use in patients who are diagnosed with non small cell lung cancer when it has already spread to other parts of their body and has a lot of PD-L1. In a phase 3 study, treatment with atezolizumab improved overall survival when compared with chemotherapy in this subgroup of patients.

The majority of patients are diagnosed at an advanced stage of the disease, which is associated with extremely poor survival and limited options, so a new treatment option is vitally needed.

Atezolizumab is also easier to tolerate, administer and requires less time spent in hospital than the current treatment option of chemotherapy.

Osimertinib treats cancer in a different way. It’s a targeted treatment designed to be effective against cancers that test positive for a faulty version of a molecule called EGFR.

The drug has been approved for patients who have had surgery to remove non small cell lung cancer that tests positive for EGFR, as there is currently a high risk of the disease returning after surgery.

In a phase 3 clinical trial, osimertinib significantly increased the amount of time patients lived for without their cancer coming back compared with a dummy drug (placebo).

The SMC also noted that osimertinib is an oral medicine that is likely to be better tolerated than other treatment options.

“Both drugs improve overall survival for non-small cell lung cancer. They showed significant potential in clinical trials as the first treatment option for some aggressive forms of lung cancer.

“Targeted drugs like these are expanding our options to treat cancer and helping more people survive cancer,” said Ferguson.

A new option for Hodgkin lymphoma

Pembrolizumab has been approved for the treatment of patients aged 3 or older with Hodgkin lymphoma whose cancer has come back or when other treatment options have failed.

The drug is another type of immunotherapy that binds to a molecule called PD-1 on T cells, preventing the cancer from switching off immune cells and allowing them to fight the disease.

In a phase 3 study, pembrolizumab stopped patients’ cancer from getting worse for longer than those being treated with brentuximab vedotin, one of the treatments currently used to treat Hodgkin lymphoma.

The SMC also noted that current treatments can be very intensive, with serious side effects, and the new drug offers a more convenient treatment option that is likely to make the treatment more tolerable for patients and their families.

“Pembrolizumab will provide another treatment for patients living with Hodgkin lymphoma that is generally well tolerated,” said Ferguson.

Not cost-effective

Selpercatinib was being considered as a treatment for adults with a type of advanced non small cell lung cancer that have a change in a gene called RET.

After careful consideration, SMC has not recommended selpercatinib to treat these patients because the evidence provided by the company that produces the drug was not strong enough to satisfy the committee that it offers value for money to NHS Scotland.

This was despite the SMC using a more flexible approach in their assessment, as it is for a rare condition where patients are likely to have a life expectancy of less than3 years with currently available treatments.

If a patient’s healthcare professional thinks a particular patient would benefit from the drug, they can still make a request to prescribe selpercatinib. All Scottish health boards have procedures in place to consider these requests.

Drug decisions for the NHS in England are made through the National Institute for Health and Care Excellence (NICE), which usually leads to adoption in Wales and Northern Ireland as well.

More on this topic

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Breast Cancer Survivor Invents Warming Bra Insert to Combat Cold Feeling of Breast Implants

In 2013, Kristen Carbone, of Providence, Rhode Island, had a preventative mastectomy to help protect herself against breast cancer after her mother died of...

FDA Approves Daratumumab plus Hyaluronidase-fihj, Carfilzomib, and Dexamethasone for Relapsed or Refractory Multiple Myeloma

On 30 November 2021, the US Food and Drug Administration (FDA) approved daratumumab plus hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) and carfilzomib (Kyprolis, Amgen,...

Thanks For Making This GivingTuesday Our Best One Yet!

We set ambitious goals for GivingTuesday, but they were driven by a time of great need. With your help, we hoped to provide food and...

Over 600 people in England set to benefit from innovative lung cancer treatment

<img width="620" height="348" src="https://34p2k13bwwzx12bgy13rwq8p-wpengine.netdna-ssl.com/wp-content/uploads/2021/05/lung_cell_cropped-hero.jpg" class="attachment-featuredImage size-featuredImage" alt="Lung cancer cell" loading="lazy" srcset="https://34p2k13bwwzx12bgy13rwq8p-wpengine.netdna-ssl.com/wp-content/uploads/2021/05/lung_cell_cropped-hero.jpg 620w, https://34p2k13bwwzx12bgy13rwq8p-wpengine.netdna-ssl.com/wp-content/uploads/2021/05/lung_cell_cropped-hero-300x168.jpg 300w, https://34p2k13bwwzx12bgy13rwq8p-wpengine.netdna-ssl.com/wp-content/uploads/2021/05/lung_cell_cropped-hero-220x123.jpg 220w, https://34p2k13bwwzx12bgy13rwq8p-wpengine.netdna-ssl.com/wp-content/uploads/2021/05/lung_cell_cropped-hero-150x84.jpg 150w" sizes="(max-width: 620px) 100vw, 620px" data-attachment-id="18781" data-permalink="https://news.cancerresearchuk.org/2020/09/11/targeted-drug-for-lung-cancer-approved-for-nhs-use-in-england/lung_cell_cropped-hero/"...

Touching a nerve: How neuroscience could advance our understanding of cancer

KTSDESIGN/SCIENCE PHOTO LIBRARY When supporters donate to our work, their combined generosity might lead to a new discovery that inches us closer to, for example,...

Nivolumab Demonstrates Clinical Benefits in a Statistically Evaluable Number of Patients with CUP

An investigator-initiated phase II study is the first to show that nivolumab has clinical activity with manageable toxicity in a statistically evaluable number of...